Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).

<h4>Background</h4>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to reduce hyperglycemia. The present study investigated the effects of a SGLT2 inhibitor, empagliflozin, on hyperglycemia in a novel rat model of non-obesity type 2 diabetes with enlarged kidney (DEK).&l...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ayaka Domon, Kentaro Katayama, Touko Sato, Yuki Tochigi, Hiroyuki Tazaki, Hiroetsu Suzuki
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7a40a4948b73485584bbc6c3ec61bdd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7a40a4948b73485584bbc6c3ec61bdd7
record_format	dspace
spelling	oai:doaj.org-article:7a40a4948b73485584bbc6c3ec61bdd72021-11-25T06:19:20ZEmpagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).1932-620310.1371/journal.pone.0251135https://doaj.org/article/7a40a4948b73485584bbc6c3ec61bdd72021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0251135https://doaj.org/toc/1932-6203<h4>Background</h4>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to reduce hyperglycemia. The present study investigated the effects of a SGLT2 inhibitor, empagliflozin, on hyperglycemia in a novel rat model of non-obesity type 2 diabetes with enlarged kidney (DEK).<h4>Methods</h4>Male DEK rats with non-fasting blood glucose concentrations ≤300 mg/dl and >300 mg/dl were classified as nondiabetic and diabetic, respectively. Groups of nondiabetic (control) and diabetic (DM-cont) rats were fed standard chow for 12 weeks, whereas another group of diabetic (DM-empa) rats was fed standard chow containing empagliflozin (300 mg/kg/day) for 12 weeks. Blood glucose, body weight, glucose tolerance, food and water intake, urinary volume, plasma and urinary biochemical parameters, and bone mineral density were measured, and their kidneys and pancreas histologically analyzed.<h4>Results</h4>Treatment with empagliflozin reduced blood glucose concentration and food intake in diabetic rats, but inhibited loss of adeps renis and led to body weight gain. Empagliflozin attenuated polyuria and polydipsia but increased plasma concentrations of total cholesterol, sodium and total protein toward normal level. Empagliflozin also significantly reduced urinary excretion of proteins and electrolytes and restored bone mineral density and plasma concentrations of valine and isoleucine to normal levels. Moreover, dilation of renal tubules and kidney enlargement were not attenuated in the DM-empa group.<h4>Conclusion</h4>The response of DEK rats to empagliflozin differed from that of other diabetic animal models, suggesting that DEK rats have unique characters for studying and evaluating the multiple biological effects of SGLT2 inhibitors. These findings also indicted that empagliflozin could ameliorate systemic metabolism and improve renal tubule function in diabetic condition.Ayaka DomonKentaro KatayamaTouko SatoYuki TochigiHiroyuki TazakiHiroetsu SuzukiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0251135 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ayaka Domon Kentaro Katayama Touko Sato Yuki Tochigi Hiroyuki Tazaki Hiroetsu Suzuki Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
description	<h4>Background</h4>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to reduce hyperglycemia. The present study investigated the effects of a SGLT2 inhibitor, empagliflozin, on hyperglycemia in a novel rat model of non-obesity type 2 diabetes with enlarged kidney (DEK).<h4>Methods</h4>Male DEK rats with non-fasting blood glucose concentrations ≤300 mg/dl and >300 mg/dl were classified as nondiabetic and diabetic, respectively. Groups of nondiabetic (control) and diabetic (DM-cont) rats were fed standard chow for 12 weeks, whereas another group of diabetic (DM-empa) rats was fed standard chow containing empagliflozin (300 mg/kg/day) for 12 weeks. Blood glucose, body weight, glucose tolerance, food and water intake, urinary volume, plasma and urinary biochemical parameters, and bone mineral density were measured, and their kidneys and pancreas histologically analyzed.<h4>Results</h4>Treatment with empagliflozin reduced blood glucose concentration and food intake in diabetic rats, but inhibited loss of adeps renis and led to body weight gain. Empagliflozin attenuated polyuria and polydipsia but increased plasma concentrations of total cholesterol, sodium and total protein toward normal level. Empagliflozin also significantly reduced urinary excretion of proteins and electrolytes and restored bone mineral density and plasma concentrations of valine and isoleucine to normal levels. Moreover, dilation of renal tubules and kidney enlargement were not attenuated in the DM-empa group.<h4>Conclusion</h4>The response of DEK rats to empagliflozin differed from that of other diabetic animal models, suggesting that DEK rats have unique characters for studying and evaluating the multiple biological effects of SGLT2 inhibitors. These findings also indicted that empagliflozin could ameliorate systemic metabolism and improve renal tubule function in diabetic condition.
format	article
author	Ayaka Domon Kentaro Katayama Touko Sato Yuki Tochigi Hiroyuki Tazaki Hiroetsu Suzuki
author_facet	Ayaka Domon Kentaro Katayama Touko Sato Yuki Tochigi Hiroyuki Tazaki Hiroetsu Suzuki
author_sort	Ayaka Domon
title	Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
title_short	Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
title_full	Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
title_fullStr	Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
title_full_unstemmed	Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
title_sort	empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (dek).
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/7a40a4948b73485584bbc6c3ec61bdd7
work_keys_str_mv	AT ayakadomon empagliflozinamelioratessymptomsofdiabetesandrenaltubulardysfunctioninaratmodelofdiabeteswithenlargedkidneydek AT kentarokatayama empagliflozinamelioratessymptomsofdiabetesandrenaltubulardysfunctioninaratmodelofdiabeteswithenlargedkidneydek AT toukosato empagliflozinamelioratessymptomsofdiabetesandrenaltubulardysfunctioninaratmodelofdiabeteswithenlargedkidneydek AT yukitochigi empagliflozinamelioratessymptomsofdiabetesandrenaltubulardysfunctioninaratmodelofdiabeteswithenlargedkidneydek AT hiroyukitazaki empagliflozinamelioratessymptomsofdiabetesandrenaltubulardysfunctioninaratmodelofdiabeteswithenlargedkidneydek AT hiroetsusuzuki empagliflozinamelioratessymptomsofdiabetesandrenaltubulardysfunctioninaratmodelofdiabeteswithenlargedkidneydek
_version_	1718413872040247296

Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).

Ejemplares similares